Amicus Therapeutics (NASDAQ:FOLD) Now Covered by Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) in a research note issued to investors on Friday morning, MarketBeat reports. The brokerage issued a buy rating and a $18.00 price objective on the biopharmaceutical company’s stock. Other analysts have also issued reports about the company. Morgan Stanley lowered their […]

Leave a Reply

Your email address will not be published.

Previous post HC Wainwright Reiterates Buy Rating for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Next post Concrete Pumping (NASDAQ:BBCP) Downgraded by UBS Group